A Global Answer to Waste? SUS ENVIRONMENT Fast-Tracks the Development of a Worldwide Waste-to-Energy Network

A Global Answer to Waste? SUS ENVIRONMENT Fast-Tracks the Development of a Worldwide Waste-to-Energy Network

SHANGHAI, Dec. 22, 2025 /PRNewswire/ -- Since the full implementation of its internationalization strategy, SUS ENVIRONMENT has been continuously driving the steady and high-quality development of the overseas business. On December 8, the Nonthaburi...

IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries

IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries

Despite challenging framework conditions such as high energy prices, the international introduction of tariffs, and bureaucratic requirements, Saxony-Anhalt is drawing a positive balance for 2025: leading companies have announced or begun...

7.8 GWh Saudi Arabia ESS Project Officially Connected to the Grid

7.8 GWh Saudi Arabia ESS Project Officially Connected to the Grid

HEFEI, China, Dec. 18, 2025 /PRNewswire/ -- The Kingdom of Saudi Arabia has officially completed grid connection of its landmark energy storage system (ESS) project with the nameplate capacity of 7.8GWh. Once fully energized, it will become the...

Historic production of graphene enhanced cement successfully completed

Historic production of graphene enhanced cement successfully completed

Highlights Production of 600 tonnes of low-carbon PureGRAPH® enhanced cement successfully completed by one of the UK's largest cement producers Graphene enhanced cement will be used by multiple end users in a range of applications, including...

Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ: PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary...

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational...

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Announcement Highlights: Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease . The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was...

Robo.ai Inc. Reaches a $180 Million Financing Agreement with ATW Partners

Robo.ai Inc. Reaches a $180 Million Financing Agreement with ATW Partners

DUBAI, UAE, Dec. 12, 2025 /PRNewswire/ -- Robo.ai Inc. (NASDAQ: AIIO), a technology platform dedicated to "AI, Smart Device and Smart Asset", today announced that it has entered into definitive agreements with ATW Partners (www.atwpartners.com) for...

Datasea Announces Breakthrough in Acoustic-Driven Brain-Computer Interface Technology

Datasea Announces Breakthrough in Acoustic-Driven Brain-Computer Interface Technology

Developing Healthcare and Intelligent Interaction Through Core Acoustic Innovation BEIJING, Dec. 11, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a global technology enterprise specializing in acoustic high-tech...

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 18
  • menu
    menu